Most commercially available antibodies produced with traditional immunization technology, using peptides or other immunogens isolated and purified from cell lysates.
Typically, mice are immunized with the antigen in groups, varying the mouse strain and antigen dosage. Pre-immune and immune sera are evaluated and mice showing the best immune response are selected for somatic cell fusion. This is the fusion of antibody-producing lymphocytes with proprietary myeloma cells from a non-antibody producing source, creating a hybridoma.
Novus Biologicals recently added novel GAT (Genomic Antibody Technology) reagents to our antibody catalog, following the formation of a partnership with SDIX, creators of the technique. SDIX's GAT antibodies represent a totally new way to think about protein immunogens.
Novus Biologicals offers an extensive antibody databasecovering all areas of biological research. Recently, we dramatically increased the scope of our antibody catalog by adding over 800 antibodies created using Genomic Antibody Technology (GAT), through a new partnership with SDIX (Strategic Diagnostics, Inc.). As we begin creating novel GAT reagents of our own, this database will expand still further – as there are many GAT antibodiesstill to be created.
Recently, we at Novus Biologicals became partners with Strategic Diagnostics Inc (SDIX), one of the largest antibodyproducers in the US. The objective was to extend our antibody database by over 800 of SDIX's polyclonal cancer antibodies, created by their unique Genomic Antibody Technology (GAT) system, as well as creating novel GAT immunoglobulins against targets specific to our own antibody catalog. However, what exactly is GAT, and why is it so superior?
